DE-ESCALATION OF TYROSINE KINASE INHIBITOR THERAPY IS SAFE IN CHRONIC MYELOID LEUKAEMIA IN DURABLE MOLECULAR RESPONSE (>= MR3 FOR >= 12 MONTHS): INITIAL RESULTS IN THE BRITISH DESTINY STUDY
HAEMATOLOGICA（2016）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要